Donor-Derived Cell-Free DNA Associated With Increased Risk of Chronic Lung Allograft Dysfunction and Mortality: Implications of Immunosuppression and Retransplantation

This study published in The Journal of Heart and Lung Transplantation evaluates the role of donor-derived cell-free DNA (dd-cfDNA) as a biomarker for predicting outcomes after lung transplantation. The authors demonstrate that elevated dd-cfDNA levels are associated with an increased risk of chronic lung allograft dysfunction (CLAD) and mortality, highlighting its value as a noninvasive marker of ongoing graft injury. Importantly, the study suggests that absolute dd-cfDNA levels may provide stronger prognostic utility than relative changes alone, offering improved risk stratification over time. These findings support the integration of molecular surveillance into routine post-transplant monitoring to enable earlier detection of graft injury and potentially guide pre-emptive interventions.  For the CTSNet global cardiothoracic surgery audience, this work is highly relevant as it represents a shift toward precision, biomarker-driven post-transplant care. By improving early detection of graft dysfunction, dd-cfDNA monitoring could enhance long-term outcomes, refine follow-up strategies, and reduce reliance on invasive surveillance methods such as transbronchial biopsy.